Lyell Immunopharma (LYEL) appoints a new CEO who recently served as the CEO of a $2.9 billion biopharmaceutical companyApr 26, 2024∙ PaidShareLyell Immunopharma (LYEL) - Dec 2022334KB ∙ PDF fileDownloadDownloadThis post is for paid subscribersSubscribeAlready a paid subscriber? Sign inPreviousNext